

: US-10-578-672A-10  
 Perfect score: 397  
 Sequence: 1 gggcaggggatgatgaa.....gtttccagagcctagccct 397

RESULT 15

ABV95296/c

ID ABV95296 standard; cDNA; 449 BP.

XX

AC ABV95296;

XX

DT 14-JAN-2003 (first entry)

XX

DE Human pancreatic cancer expressed cDNA SEQ ID NO 704.

XX

KW Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;

KW

cytostatic; tumour; gene; ss.

XX

OS Homo sapiens.

XX

PN WO200260317-A2.

XX

PD 08-AUG-2002.

XX

PF 30-JAN-2002; 2002WO-US002781.

XX

PR 30-JAN-2001; 2001US-0265305P.

PR

31-JAN-2001; 2001US-0265682P.

PR

09-FEB-2001; 2001US-0267568P.

PR

21-MAR-2001; 2001US-0278651P.

PR

29-APR-2001; 2001US-0287112P.

PR

16-MAY-2001; 2001US-0291631P.

PR

12-JUL-2001; 2001US-0305484P.

PR

20-AUG-2001; 2001US-0313999P.

PR

27-NOV-2001; 2001US-0333626P.

XX

PA (CORI-) CORIXA CORP.

XX

PI Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WI, Jiang Y;

XX

DR WPI; 2002-627435/67.

XX

PT New isolated polynucleotide and pancreatic tumor polypeptides, useful for

PT

diagnosing, preventing and/or treating cancer, particularly pancreatic

PT

cancer.

XX

PS Claim 1; SEQ ID NO 704; 300pp + Sequence Listing; English.

XX

CC The invention relates to an isolated polynucleotide (I) comprising: (a)

CC

any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)

CC

complements of (a); (c) sequences consisting of at least 20 contiguous

CC

residues of (a); (d) sequences that hybridize to (a), under moderately

CC

stringent conditions; (e) sequences having at least 75% or 90% identity

CC

to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-

CC

ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer

CC

in a patient and compositions comprising polypeptides, polynucleotides,

CC

antibodies, fusion proteins, T cell populations and antigen presenting

CC

cells expressing the polypeptide are useful in treating pancreatic cancer

CC

and stimulating an immune response. The polynucleotides can be used as

CC

probes or primers for nucleic acid hybridisation, in the design and

CC

preparation of ribozyme molecules for inhibiting expression of the tumour

CC

polypeptides and proteins in the tumour cells, in vaccines and for gene

CC

therapy. Note: The sequence data for this patent did not form part of the

CC

printed specification, but was obtained in electronic format directly

CC

from WIPO at ftp.wipo.int/pub/published\_pat\_sequences

CC

XX

SQ Sequence 449 BP; 143 A; 91 C; 89 G; 125 T; 0 U; 1 Other;

Query Match 53.5%; Score 212.4; DB 6; Length 449;  
 Best Local Similarity 97.0%; Pred. No. 4.7e-38;  
 Matches 227; Conservative 0; Mismatches 6; Indels 1; Gaps 1;

Qy 2 GCCCAGGGGATGATATGAATGTCACAGGAGGAGACACCTTCGTCTTTGTTTCAAGAAAA 61  
Db 233 GGTGGGGGGATGATATGAATGTCACAGGAGGAGACACCTTCGTCTTTGTTTCAAGAAAA 174

Qy 62 GTTGATGTGCCATTTCCTTAATATACAAGAGAAATATTGAAAATATATTGAAAGAGCAAT 121  
Db 137 G-TGATGTGCCATTTCCTTAATATACAAGAGAAATATTGAAAATATATTGAAAGAGCAAT 115

Qy 122 TTTAAATATTTTGGCTATGTGCAAAATTTATTTTCTGTATAGCAAGATTCCTT 181  
Db 122 TTTAAATATTTTGGCTATGTGCAAAATTTATTTTCTGTATAGCAAGATTCCTT 55

Qy 184 TGTAGAAAAAAATGATATTTTCATTACGCCAAAAAGCCTATTTCCTTTTGT 235  
Db 54 TGTAGAAAAAAATGATATTTTCATTACGCCAAAAAGCCTATTTCCTTTTGT 1